TaiGen Biopharmaceuticals Holdings Limited (4157.TWO)
TWD 8.97
(-7.33%)
TWD 8.97
(-7.33%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.22 Billion TWD | 17.46% |
| 2022 | 1.04 Billion TWD | -24.83% |
| 2021 | 1.39 Billion TWD | 150.3% |
| 2020 | 556.44 Million TWD | -41.19% |
| 2019 | 946.1 Million TWD | -20.34% |
| 2018 | 1.18 Billion TWD | -21.97% |
| 2017 | 1.52 Billion TWD | 84.85% |
| 2016 | 823.44 Million TWD | 31.65% |
| 2015 | 625.46 Million TWD | -43.05% |
| 2014 | 1.09 Billion TWD | 125.74% |
| 2013 | 486.48 Million TWD | -33.72% |
| 2012 | 733.94 Million TWD | 20.22% |
| 2011 | 610.52 Million TWD | -45.15% |
| 2010 | 1.11 Billion TWD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.28 Billion TWD | 5.84% |
| 2024 Q1 | 1.21 Billion TWD | -1.33% |
| 2023 Q3 | 1.02 Billion TWD | -3.98% |
| 2023 Q4 | 1.22 Billion TWD | 19.51% |
| 2023 FY | 1.22 Billion TWD | 17.46% |
| 2023 Q1 | 1 Billion TWD | -4.43% |
| 2023 Q2 | 1.07 Billion TWD | 7.1% |
| 2022 Q1 | 1.3 Billion TWD | -6.47% |
| 2022 FY | 1.04 Billion TWD | -24.83% |
| 2022 Q4 | 1.04 Billion TWD | -10.29% |
| 2022 Q2 | 1.23 Billion TWD | -5.51% |
| 2022 Q3 | 1.16 Billion TWD | -5.18% |
| 2021 Q3 | 1.45 Billion TWD | -8.82% |
| 2021 Q4 | 1.39 Billion TWD | -3.99% |
| 2021 Q1 | 458.44 Million TWD | -17.61% |
| 2021 Q2 | 1.59 Billion TWD | 247.06% |
| 2021 FY | 1.39 Billion TWD | 150.3% |
| 2020 Q2 | 709.2 Million TWD | -13.3% |
| 2020 Q1 | 818 Million TWD | -13.54% |
| 2020 Q3 | 610 Million TWD | -13.99% |
| 2020 FY | 556.44 Million TWD | -41.19% |
| 2020 Q4 | 556.44 Million TWD | -8.78% |
| 2019 Q1 | 1.24 Billion TWD | 4.91% |
| 2019 Q4 | 946.1 Million TWD | -17.51% |
| 2019 FY | 946.1 Million TWD | -20.34% |
| 2019 Q3 | 1.14 Billion TWD | -12.44% |
| 2019 Q2 | 1.3 Billion TWD | 5.12% |
| 2018 Q4 | 1.18 Billion TWD | -6.84% |
| 2018 FY | 1.18 Billion TWD | -21.97% |
| 2018 Q3 | 1.27 Billion TWD | -8.69% |
| 2018 Q2 | 1.39 Billion TWD | -5.54% |
| 2018 Q1 | 1.47 Billion TWD | -2.9% |
| 2017 FY | 1.52 Billion TWD | 84.85% |
| 2017 Q2 | 1.69 Billion TWD | 27.07% |
| 2017 Q3 | 1.66 Billion TWD | -2.02% |
| 2017 Q4 | 1.52 Billion TWD | -8.49% |
| 2017 Q1 | 1.33 Billion TWD | 62.25% |
| 2016 FY | 823.44 Million TWD | 31.65% |
| 2016 Q4 | 823.44 Million TWD | -3.73% |
| 2016 Q3 | 855.31 Million TWD | -8.67% |
| 2016 Q2 | 936.48 Million TWD | -4.59% |
| 2016 Q1 | 981.51 Million TWD | 56.93% |
| 2015 Q2 | 852.81 Million TWD | -12.42% |
| 2015 FY | 625.46 Million TWD | -43.05% |
| 2015 Q4 | 625.46 Million TWD | -16.35% |
| 2015 Q3 | 747.7 Million TWD | -12.32% |
| 2015 Q1 | 973.78 Million TWD | -11.33% |
| 2014 Q2 | 1.3 Billion TWD | -11.54% |
| 2014 Q3 | 1.2 Billion TWD | -8.22% |
| 2014 Q4 | 1.09 Billion TWD | -8.56% |
| 2014 Q1 | 1.47 Billion TWD | 204.09% |
| 2014 FY | 1.09 Billion TWD | 125.74% |
| 2013 FY | 486.48 Million TWD | -33.72% |
| 2013 Q1 | - TWD | -100.0% |
| 2013 Q2 | 623.58 Million TWD | 0.0% |
| 2013 Q3 | 619.8 Million TWD | -0.61% |
| 2013 Q4 | 486.48 Million TWD | -21.51% |
| 2012 Q4 | 733.94 Million TWD | 0.0% |
| 2012 FY | 733.94 Million TWD | 20.22% |
| 2011 FY | 610.52 Million TWD | -45.15% |
| 2010 FY | 1.11 Billion TWD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| SYN-TECH Chem. & Pharm. Co., Ltd. | 2.9 Billion TWD | 57.605% |
| Level Biotechnology Inc. | 822.67 Million TWD | -49.493% |
| Sagittarius Life Science Corp | 664.72 Million TWD | -85.015% |
| NeoCore Technology Co., Ltd. | 548.74 Million TWD | -124.117% |
| TaiMed Biologics Inc. | 3.89 Billion TWD | 68.416% |
| GlycoNex Incorporation | 1.55 Billion TWD | 20.799% |
| VBI | 452.1 Million TWD | -172.027% |
| GeneReach Biotechnology Corp. | 1.17 Billion TWD | -4.565% |
| Taiwan Advance Bio-Pharmaceutical Inc. | 748.57 Million TWD | -64.291% |
| Visgeneer Inc. | 397.17 Million TWD | -209.646% |
| Mycenax Biotech Inc. | 3.77 Billion TWD | 67.382% |
| Sunmax Biotechnology Co., Ltd. | 2.15 Billion TWD | 43.038% |
| G&E Herbal Biotechnology Co., Ltd. | 883.09 Million TWD | -39.265% |
| Medigen Vaccine Biologics Corporation | 6.09 Billion TWD | 79.814% |
| TaiwanJ Pharmaceuticals Co., Ltd. | 73.55 Million TWD | -1571.93% |
| Enimmune corporation | 604.82 Million TWD | -103.337% |
| TaiRx, Inc. | 833.74 Million TWD | -47.508% |
| CHO Pharma, Inc. | 3.08 Billion TWD | 60.148% |
| EirGenix Inc. | 11.16 Billion TWD | 88.982% |
| BioLASCO Taiwan Co., Ltd. | 573.13 Million TWD | -114.579% |
| Sunny Pharmtech Inc. | 1.71 Billion TWD | 28.179% |
| Lin BioScience, Inc. | 3.59 Billion TWD | 65.807% |
| BioGend Therapeutics Co., Ltd. | 1.05 Billion TWD | -17.074% |
| Feng Chi Biotech Corp. | 301.03 Million TWD | -308.541% |
| Bio Preventive Medicine Corp. | 264.65 Million TWD | -364.691% |
| Lukas Biomedical Inc. | 441.19 Million TWD | -178.754% |
| RBC Bioscience Corporation | 753.79 Million TWD | -63.154% |
| BiOptic Inc. | 613.77 Million TWD | -100.373% |
| BRIM Biotechnology, Inc. | 1.77 Billion TWD | 30.856% |
| Shine-On BioMedical Co.,Ltd. | 1.15 Billion TWD | -6.047% |
| Great Novel Therapeutics Biotech & Medicals | 644.84 Million TWD | -90.717% |
| Syngen Biotech Co.,Ltd. | 3.1 Billion TWD | 60.408% |
| Anti-Microbial Savior BioteQ Co., Ltd | 128.04 Million TWD | -860.458% |
| SynCore Biotechnology Co.,Ltd | 378.36 Million TWD | -225.043% |
| Genomics BioSci & Tech. Co.,Ltd. | 1.13 Billion TWD | -8.466% |
| Neith Corporation | 192.15 Million TWD | -540.031% |
| Advagene Biopharma Co., Ltd. | 147.93 Million TWD | -731.342% |
| NaviFUS Corp. | 490.53 Million TWD | -150.714% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | 1.22 Billion TWD | -0.336% |
| Sinew Pharma Inc. | 1.36 Billion TWD | 9.795% |
| Andros Pharmaceuticals Co.,Ltd | 529.14 Million TWD | -132.419% |
| Greenyn Biotechnology Co., Ltd | 1.16 Billion TWD | -5.894% |
| Lumosa Therapeutics Co., Ltd. | 1.65 Billion TWD | 25.747% |
| AP Biosciences Inc | 890.75 Million TWD | -38.067% |
| Medigen Biotechnology Corp. | 8.52 Billion TWD | 85.578% |
| 3D Global Biotech Inc. | 324.14 Million TWD | -279.406% |
| Pharmosa Biopharm Inc. | 1.33 Billion TWD | 7.784% |
| Intech Biopharm Corporation | 2.71 Billion TWD | 54.636% |
| Oneness Biotech Co., Ltd. | 15.36 Billion TWD | 91.995% |
| Eusol Biotech Co.,Ltd. | 410.25 Million TWD | -199.772% |
| TWi Biotechnology, Inc. | 396.85 Million TWD | -209.899% |
| Ever Supreme Bio Technology Co., Ltd | 2.07 Billion TWD | 40.757% |
| TCI GENE Inc. | 1.16 Billion TWD | -5.48% |
| MegaPro Biomedical Co., Ltd | 294.58 Million TWD | -317.487% |
| Senhwa Biosciences, Inc. | 1.36 Billion TWD | 9.792% |
| Taiwan Bio Therapeutics Co., Ltd | 941.76 Million TWD | -30.589% |
| NatureWise Biotech & Medicals Corporation | 698.45 Million TWD | -76.081% |
| PharmaEngine, Inc. | 3.95 Billion TWD | 68.896% |
| Savior Lifetec Corporation | 3.82 Billion TWD | 67.828% |
| OBI Pharma, Inc. | 5.6 Billion TWD | 78.054% |
| Meribank Biotech Co., Ltd | 1.06 Billion TWD | -15.803% |
| Acepodia, Inc. | 6.81 Billion TWD | 81.963% |
| Caliway Biopharmaceuticals Co., Ltd. | 3.82 Billion TWD | 67.86% |